Next Clinics | AI Transformation Index

Overview

Next Clinics operates a pan-European network of IVF clinics, bio banks, and specialized laboratories, generating fee-for-service revenue from assisted reproduction treatments (including egg/sperm donation, fertility preservation), plastic surgery, and medical tourism coordination across 8 countries.

Executive Summary

Next Clinics is a structurally durable fertility clinic operator whose core business — licensed reproductive medicine requiring physical infrastructure, surgical capacity, and multi-country regulatory approvals — is essentially immune to AI substitution or disintermediation. The AI opportunity is real but bounded: embryo selection algorithms, outcome prediction, and medical tourism automation offer meaningful clinical and operational improvements, but physical capacity constraints prevent the order-of-magnitude throughput transformation possible in pure cognitive-labor businesses. For a PE investor, the AI thesis here is clinical quality differentiation and outcome-based patient acquisition rather than cost-of-service compression — valuable, but not the same scale of transformation available in, say, a claims processing or benefits administration business.

Durability Rationale

Next Clinics' durability is anchored in the irreducibly physical and regulated nature of reproductive medicine: IVF procedures require licensed surgeons, accredited embryology laboratories, cryogenic infrastructure, and country-specific regulatory approvals that no AI-native entrant can acquire through software development. The profit pool sits firmly at the clinical operator layer with no credible adjacent layer poised to extract value between patients and clinics, and the multi-jurisdictional regulatory complexity across 8 European countries is itself a formidable barrier to new entry. Patient trust and the emotional stakes of fertility treatment further entrench switching costs, making this one of the more structurally durable healthcare verticals against AI disruption.

Opportunity Rationale

AI's potential for Next Clinics is real but structurally bounded by the physical capacity constraints inherent to clinical operations — the bottleneck is theatre time and licensed embryologists, not analytical bandwidth. The highest-value AI opportunities lie in embryo selection and outcome prediction (where AI-assisted morphokinetic analysis can measurably improve success rates), multi-lingual medical tourism coordination automation, and predictive stimulation protocol optimization leveraging proprietary cycle outcome data. The company's basic-IT sophistication and small engineering footprint mean the unrealized potential is genuine and would require external catalysis — but the scope of transformation is more clinical quality improvement than operational cost compression at scale.

Key Risks